Thus, our data suggest that augmented CAR-T cell functions in solid tumors may paradoxically depend on a unique subpopulation of PD-1high CAR-T cells that possess optimal anti-cancer functions and that a combination strategy with a PD-1 inhibition is required to maximize therapeutic functions of CAR-T cells. Here, PDCD1 is linked to cancer.